Abstract
The most important goal of modern surgical oncology is to utilize the less aggressive methods while maintaining radicalism. The evolution of imaging techniques and the option of using screening tests more and more reliable and effective have permitted an increasingly early diagnosis, identifying malignant lesions of ever smaller dimensions. This is particularly common in the case of breast cancer, where clinically occult lesions are diagnosed with increasing frequency, now represents approximately 25–35% of all breast cancers diagnosed in developed countries [1, 2].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Franceschi D, Crowe J, Zollinger R, Duchesneau R, Shenk R, Stefanek G, Shuck JM (1990) Biopsy of the breast for mammographically detected lesions. Surg Gynecol Obstet 171(6):449–455
Goedde TA, Frykberg ER, Crump JM, Lay SF, Turetsky DB, Linden SS (1992) The impact of mammography on breast biopsy. Am Surg 58(11):661–666
Querci della Rovere G (1996) Localization of impalpable breast lesions. A surgical approach. Eur J Surg Oncol 22:478–482
Silverstein MJ, Gamagami P, Rosser RJ, Gierson ED, Colburn WJ, Handel N et al (1987) Hooked-wire directed breast biopsy and overpenetrated mammography. Cancer 59:715–722
Besic N, Zgajnar J, Hocevar M, Gierson ED, Colburn WJ, Handel N et al (2002) Breast biopsy with wire localization: factors influencing complete excision of nonpalpable carcinoma. Eur Radiol 12:2684–2689
Davis PS, Wechsler RJ, Feig SA (1983) Migration of breast biopsy localization wire. Am J Radiol 141:929–930
Homer MJ (1983) Transection of the localization wire hooked During breast biopsy. Am J Roentgenol 141:929–930
Tykka H, Castren-Person M, Sjoblom M (1993) Pneumothorax Caused by hooked wire localization of an impalpable breast lesion detected by mammography. Breast 2:52–53
Luini A, Zurrida S, Galimberti V, Paganelli G (1998) Radioguided surgery of occult breast lesions. Eur J Cancer 34(1):204–205
De Cicco C, Pizzamiglio M, Trifirò G, Luini A, Ferrari M, Prisco G, Galimberti V, Cassano E, Viale G, Intra M, Veronesi P, Paganelli G (2002) Radioguided occult lesion localization (ROLL) and surgical biopsy in breast cancer. Technical aspects. Q J Nucl Med 46:145–151
Paganelli G, Luini A, Veronesi U (2002) Radioguided occult lesion localization (ROLL) in breast cancer: maximizing efficacy, minimizing mutilation. Ann Oncol 13:1839–1840
Monti S, Galimberti V, Trifiro G, De Cicco C, Peradze N, Brenelli F, Fernandez-Rodriguez J, Rotmensz N, Latronico A, Berrettini A et al (2007) Occult breast lesion localization plus sentinel node biopsy (SNOLL): experience with 959 patients at the European Institute of Oncology. Ann Surg Oncol 14(10):2928–2931
Postma EL, Koffijberg H, Verkooijen HM, Witkamp AJ, van den Bosch MA, van Hillegersberg R (2013) Cost-effectiveness of radioguided occult lesion localization (ROLL) versus wire-guided localization (WGL) in breast conserving surgery for nonpalpable breast cancer: results from a randomized controlled multicenter trial. Ann Surg Oncol 20(7):2219–2226
Veronesi U, Luini A, Botteri E, Zurrida S, Monti S, Galimberti V, Cassano E, Latronico A, Pizzamiglio M, Viale G, Vezzoli D, Rotmensz N, Musmeci S, Bassi F, Burgoa L, Maisonneuve P, Paganelli G, Veronesi P (2010) Nonpalpable breast carcinomas: long-term evaluation of 1,258 cases. Oncologist 15(12):1248–1252
Lovrics PJ, Cornacchi SD, Vora R, Goldsmith CH, Kahnamoui K (2011) Systematic review of radioguided surgery for non-palpable breast cancer. EJSO 37:388–397
Postma EL, Verkooijen HM, van Esser S et al (2012) Efficacy of ‘radioguided occult lesion localisation’ (ROLL) versus ‘wireguided localisation’ (WGL) in breast conserving surgery for nonpalpable breast cancer: a randomised controlled multicentre trial. Breast Cancer Res Treat 136:469–478
Paganelli G, Gilardi L, Veronesi U (2013) Improper use of “radioguided occult lesion localization” (ROLL) technique leads to misleading conclusions. Breast Cancer Res Treat 139:287–290
van der Noordaa ME, Pengel KE, Groen E, van Werkhoven E, Rutgers EJ, Loo CE, Vogel W, Vrancken Peeters MJ (2015) The use of radioactive iodine-125 seed localization in patients with non-palpable breast cancer: a comparison with the radioguided occult lesion localization with 99m technetium. Eur J Surg Oncol 41(4):553–558
Chan BK, Wiseberg-Firtell JA, Jois RH, Jensen K, Audisio RA (2015) Localization techniques for guided surgical excision of non-palpable breast lesions. Cochrane Database Syst Rev 12:CD009206. doi:10.1002/14651858.CD009206.pub2
Kay Jamieson J, Dobson JF (1907) On the lymphatic system of the stomach. Lancet 169(4364):1061–1066
Gould EA, Winship T, Philbin PH, Kerr HH (1960) Observations on a “sentinel node” in cancer of the parotid. Cancer 13:77–78
Cabanas RM (1977) An approach for the treatment of penile carcinoma. Cancer 39(2):456–466
Eshima D, Fauconnier T, Eshima L, Thornback JR (2000) Radiopharmaceuticals for lymphoscintigraphy: including dosimetry and radiation considerations. Semin Nucl Med 30:25–32
De Cicco C, Cremonesi M, Luini A, Bartolomei M, Grana C, Prisco G, Galimberti V, Calza P, Viale G, Veronesi U, Paganelli G (1998) Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med 39:2080–2084
Henze E, Schelbert HR, Collins JD et al (1982) Lymphoscintigraphy with 99mTc-labeled dextran. J Nucl Med 23:923–929
Alex JC, Weaver DL, Fairbank JT, Rankin BS, Krag DN (1993) Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol 2(5):303–308
Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, Costa A, De Cicco C, Geraghty JG, Luini A, Sacchini V, Veronesi P (1997) Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349:1864–1867
Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553
White RL, Wilke LG (2004) Update on the NSABP and ACOSOG breast cancer sentinel node trials. Am Surg 70(5):420–424
Krag DN, Julian TB, Harlow SP, Weaver DL, Ashikaga T, Bryant J et al (2003) NSABP-32: phase III, randomized trial comparing axillary resection with sentinel lymph node dissection: a description of the trial. Ann Surg Oncol 11(3):208S–210S
Bergqvist L, Stundberg R, Ryden S, Strand S-E (1987) The “critical colloid dose” in studies of reticuloendothelial function. J Nucl Med 28:1424–1429
Strand SE, Bergqvist L (1989) Radiolabeled colloids and macromolecules in the lymphatic system. Crit Rev Ther Drug Carrier Syst 6:211–218
Tsopelas C (2001) Particles size analysis of 99mTc-labeled and unlabeled antimony trisulfide and rhenium sulfide colloids intended for lymphoscintigraphic application. J Nucl Med 42:460–466
Povoski SP, Olsen JO, Young DC, Clarke J, Burak WE, Walker MJ et al (2006) Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol 13:1412–1421
Rodier JF, Velten M, Wilt M, Martel P, Ferron G, Vaini-Elies V et al (2007) Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial. J Clin Oncol 25:3664–3669
Noguchi M, Inokuchi M, Zen Y (2009) Complement of peritumoral and subareolar injection in breast cancer sentinel lymph node biopsy. J Surg Oncol 100:100–105
Argon AM, Duygun U, Acar E, Daglioz G, Yenjay L, Zekioglu O et al (2006) The use of periareolar intradermal Tc-99m tin colloid and peritumoral intraparenchymal isosulfan blue dye injections for determination of the sentinel lymph node. Clin Nucl Med 31:795–800
Suami H, Pan WR, Mann GB, Taylor GI (2008) The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study. Ann Surg Oncol 15:863–871
Gentilini O, Trifirò G, Soteldo J, Luini A, Intra M, Galimberti V, Veronesi P, Silva L, Gandini S, Paganelli G, Veronesi U (2006) Sentinel lymph node biopsy in multicentric breast cancer. The experience of the European Institute of Oncology. Eur J Surg Oncol 32(5):507–510
van der Ploeg IMC, Valdes Olmos RA, Kroon BB, Nieweg OE (2008) The hybrid SPECT/CT as an additional lymphatic mapping tool in patients with breast cancer. World J Surg 32:1930–1934
Giammarile F, Alazraki N, Aarsvold JN, Audisio RA, Glass E, Grant SF, Kunikowska J, Leidenius M, Moncayo VM, Uren RF, Oyen WJG, Valdés Olmos RA, Sicart SV (2013) The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging 40:1932–1947
Kaufmann M, Morrow M, von Minckwitz G, Harris JR, Biedenkopf Expert Panel Members (2010) Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer 116:1184–1191
National Comprehensive Cancer Network (NCCN) (2014) NCCN Clinical Practice Guidelines in Oncology Breast Cancer. Version 1. 2014
Galimberti V, Cole BF, Zurrida S et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14:297–305
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, and the Panel members (2011) Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747
Zujewski J, Eng-Wong J (2005) Sentinel lymph node biopsy in the management of ductal carcinoma in situ. Clin Breast Cancer 6:216–222
Intra M, Rotmensz N, Veronesi P, Colleoni M, Iodice S, Paganelli G et al (2008) Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European Institute of Oncology on 854 patients in 10 years. Ann Surg 247:315–319
Taback B, Nguyen P, Hansen N, Edwards GK, Conway K, Giuliano AE (2006) Sentinel lymph node biopsy for local recurrence of breast cancer after breast-conserving therapy. Ann Surg Oncol 13:1099–1104
Port ER, Garcia-Etienne CA, Park J et al (2007) Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence. Ann Surg Oncol 14:2209–2214
Kaur P, Kiluk JV, Meade T et al (2011) Sentinel lymph node biopsy in patients with previous ipsilateral complete axillary lymph node dissection. Ann Surg Oncol 18:727–732
Gentilini O, Cremonesi M, Trifirò G et al (2004) Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol 15:1348–1351
Mondi MM, Cuenca RE, Ollila DW et al (2007) Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann Surg Oncol 14:218–221
Steenvoorde P, Pauwels EK, Harding LK et al (1998) Diagnostic nuclear medicine and risk for the fetus. Eur J Nucl Med 25:193–199
Donegan WL (1977) The influence of untreated internal mammary metastases upon the course of mammary cancer. Cancer 39:533–538
Cody HS III, Urban JA (1995) Internal mammary node status: a major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol 2:32–37
Sugg SL, Ferguson DJ, Posner MC et al (2000) Should internal mammary nodes be sampled in the sentinel lymph node era? Ann Surg Oncol 7:188–192
Veronesi U, Cascinelli N, Bufalino R, Morabito A, Greco M, Galluzzo D, Delle Donne V, De Lellis R, Piotti P, Sacchini V et al (1983) Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg 198(6):681–684
Paganelli G, Galimberti V, Trifirò G, Travaini L, De Cicco C, Mazzarol G, Intra M, Rocca P, Prisco G, Veronesi U (2002) Internal mammary node lymphoscintigraphy and biopsy in breast cancer. Q J Nucl Med 46:138–144
Veronesi U, Marubini E, Mariani L, Valagussa P, Zucali R (1999) The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer 35:1320–1325
Leidenius MH, Krogerus LA, Toivonen TS, Leppänen EA, von Smitten KA (2006) The clinical value of parasternal sentinel node biopsy in breast cancer. Ann Surg Oncol 13:321–326
Ahmed M, Douek M (2013) Sentinel node and occult lesion localization (SNOLL): a systematic review. Breast 22:1034–1040
Rescigno J, Zampell JC, Axelrod D (2009) Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy. Ann Surg Oncol 16:687–696
Leong SP, Shen ZZ, Liu TJ et al (2010) Is breast cancer the same disease in Asian and Western countries? World J Surg 34:2308–2324
Ahmed M, Purushotham AD, Douek M (2014) Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol 15:351–362
Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202(3):654–662
Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20(2):379–387
Norum J, Andreassen T (2000) Screening for metastatic disease in newly diagnosed breast cancer patients. What is cost-effective? Anticancer Res 20:2193–2196
Avril N, Schelling M, Dose J, Weber WA, Schwaiger M (1999) Utility of PET in Breast Cancer. Clin Positron Imaging 2(5):261–271
Buscombe JR, Holloway B, Roche N, Bombardieri E (2004) Position of nuclear medicine modalities in the diagnostic work-up of breast cancer. Q J Nucl Med Mol Imaging 48(2):109–118
Cermik TF, Mavi A, Basu S, Alavi A (2008) Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging 35:475–483
Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18:3495–3502
Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F et al (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42:9–16
Sanli Y, Kuyumcu S, Ozkan ZG, Işık G, Karanlik H, Guzelbey B et al (2012) Increased FDG uptake in breast cancer is associated with prognostic factors. Ann Nucl Med 26:345–350
Kim BS, Sung SH (2012) Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med 26:175–183
Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N et al (2008) Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 38:250–258
Koo HR, Park JS, Kang KW, Cho N, Chang JM, Bae MS, Kim WH, Lee SH, Kim MY, Kim JY, Seo M (2014) Moon WK 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur Radiol 24(3):610–618
Kitajima K, Fukushima K, Miyoshi Y, Nishimukai A, Hirota S, Igarashi Y, Katsuura T, Maruyama K, Hirota S (2015) Association between 18F-FDG uptake and molecular subtype of breast cancer. Eur J Nucl Med Mol Imaging 42(9):1371–1377
Eo JS, Chun IK, Paeng JC, Kang KW, Lee SM, Han W, Noh DY, Chung JK, Lee DS (2012) Imaging sensitivity of dedicated positron emission mammography in relation to tumor size. Breast 21(1):66–71
Weinberg IN (2006) Applications for positron emission mammography. Phys Med 21(Suppl 1):132–137
Veronesi U, De Cicco C, Galimberti E, Fernandez JR, Rotmensz N, Viale G et al (2007) A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 18:473–478
Wahl R, Siegel BA, Coleman RE, Gatsonis CG (2004) Prospective multicenter study of axillary nodal staging by Positron Emission Tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 22:277–285
Monzawa S, Adachi S, Suzuki K, Hirokaga K, Takao S, Sakuma T et al (2009) Diagnostic performance of fluorodeoxyglucose- positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT. Ann Nucl Med 23:855–861
Kumar R, Zhuang H, Schnall M, Conant E, Damia S, Weinstein S et al (2006) FDG PET positive lymph nodes are highly predictive of metastases in breast cancer. Nucl Med Commun 27:231–236
Vinh-Hung V, Everaert H, Lamote J, Voordeckers M, van Parijs H, Vanhoeij M et al (2012) Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging 39(10):1618–1627
Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N et al (2008) Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 19:1249–1254
Ng SP, David S, Alamgeer M, Ganju V (2015) Impact of pretreatment combined (18)F-fluorodeoxyglucose positron emission tomography/computed tomography staging on radiation therapy treatment decisions in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 93:111–117
Koolen BB, Vrancken Peeters M-JTFD, Aukema TS, Vogel WV, Oldenburg HAS, van der Hage JA et al (2012) 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat 131:117–126
Segaert I, Mottaghy F, Ceyssens S, De Wever W, Stroobants S, Van Ongeval C et al (2010) Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J 6:617–624
Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaria G et al (2008) Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 26:4746–4751
Groheux D, Giacchetti S, Espié M, Vercellino L, Hamy A-S, Delord M et al (2011) The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med 52:1526–1534
Bernsdorf M, Berthelsen AK, Wielenga VT, Kroman N, Teilum D, Binderup T et al (2012) Preoperative PET/CT in early stage breast cancer. Ann Oncol 23(9):2277–2282
Aukema TS, Straver ME, Vrancken Peeters M-JTFD, Russell NS, Gilhuijs KGA, Vogel WV et al (2010) Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer 46:3205–3210
Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35(13):1773–1782
Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150S
Peterson JJ, Kransdorf MJ, O’Connor MI (2003) Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop Relat Res 415(Suppl):S120–S128
Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, Nasu S, Suzuki Y, Yasuda S, Shohtsu A (2001) Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 22(8):875–879
Morris PG, Lynch C, Feeney JN, Patil S, Howard J, Larson SM, Dickler M, Hudis CA, Jochelson M, McArthur HL (2010) Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol 28(19):3154–3159
Avril N, Sassen S, Roylance R (2009) Response to therapy in breast cancer. J Nucl Med 50(suppl 1):55S–63S
Du Y, Cullum I, Illidge TM, Ell PJ (2007) Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 25(23):3440–3447
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Hamaoka T, Madewell JE, Podoloff DA et al (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22:2942–2953
Schneider JA, Divgi CR, Scott AM et al (1994) Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med 35:1748–1752
Huyge V, Garcia C, Alexiou J, Ameye L, Vanderlinden B, Lemort M, Bergmann P, Awada A, Body JJ, Flamen P (2010) Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol) 22(10):818–827
Rousseau C, Devillers A, Campone M, Campion L, Ferrer L, Sagan C et al (2011) FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. Eur J Nucl Med Mol Imaging 38:1029–1036
Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L et al (2007) [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 34:1915–1924
Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A et al (2012) Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol 23:2572–2577
Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD et al (2013) FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast 22:691–697
Grassetto G, Fornasiero A, Otello D, Bonciarelli G, Rossi E, Nashimben O, Minicozzi AM, Crepaldi G, Pasini F, Facci E, Mandoliti G, Marzola MC, Al-Nahhas A, Rubello D (2011) 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study. Eur J Radiol 80(3):828–833
Evangelista L, Baretta Z, Vinante L, Cervino AR, Gregianin M, Ghiotto C, Saladini G, Sotti G (2011) Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer. Eur J Nucl Med Mol Imaging 38(2):293–301
Champion L, Brain E, Giraudet AL, Le Stanc E, Wartski M, Edeline V, Madar O, Bellet D, Pecking A, Alberini JL (2011) Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer 117(8):1621–1629
Cochet A, David S, Moodie K, Drummond E, Dutu G, MacManus M, Chua B, Hicks RJ (2014) The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification. Cancer Imaging 14:13
Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS (2014) Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer. PLoS One 9(12):115–127
Aukema TS, Rutgers EJ, Vogel WV, Teertstra HJ, Oldenburg HS, Vrancken Peeters MT, Wesseling J, Russell NS, Valdés Olmos RA (2010) The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol 36(4):387–392
Vallabhajosula S (2007) (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 37(6):400–419
Sundararajan L, Linden HM, Link JM, Krohn KA, Mankoff DA (2007) 18F-Fluoroestradiol. Semin Nucl Med 37:470–476
Baum RP, Prasad V, Müller D, Schuchardt C, Orlava A, Wennborg A et al (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled Affibody molecules. J Nucl Med 51:892–897
Dijkers EC, Oude Munnink TH, Kosterink JG, Browers AH, Jager PL, de Jong JR et al (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87:586–592
Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, Shousha S, Coombes RC, Aboagye EO (2005) Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 65(21):10104–10112
Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34(9):1339–1347
Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, Czernin J, Phelps ME, Silverman DH (2006) Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8(1):36–42
Peterson LM, Mankoff DA, Lawton T, Yagle K, Schubert EK, Stekhova S, Gown A, Link JM, Tewson T, Krohn KA (2008) Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 49(3):367–374
Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G et al (2009) Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20:1499–1504
Sun Y, Yang Z, Zhang Y, Xue J, Wang M, Shi W, Zhu B, Hu S, Yao Z, Pan H, Zhang Y (2015) The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients. PLoS One 10(1):e0116341. doi:10.1371/journal.pone.0116341
van Kruchten M, Glaudemans AW, de Vries EF, Beets-Tan RG, Schröder CP, Dierckx RA, de Vries EG, Hospers GA (2012) PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med 53(2):182–190
Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK et al (2006) Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24:2793–2799
Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T (2016) Phase I study of 68Ga-HER2-Nanobody for PET/CT assessment of HER2-expression in breast carcinoma. J Nucl Med 57(1):27–33. Oct 8. pii: jnumed.115.162024. [Epub ahead of print]
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Paganelli, G., Matteucci, F., Gilardi, L. (2017). Nuclear Medicine in the Clinical Management (ROLL, SNB, and PET). In: Veronesi, U., Goldhirsch, A., Veronesi, P., Gentilini, O., Leonardi, M. (eds) Breast Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-48848-6_19
Download citation
DOI: https://doi.org/10.1007/978-3-319-48848-6_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-48846-2
Online ISBN: 978-3-319-48848-6
eBook Packages: MedicineMedicine (R0)